At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 128 enrolled
Drug / intervention
serlopitant +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled, Study of Neurokinin-1 Receptor Antagonist Serlopitant in Subjects With Prurigo Nodularis
In Brief
A Phase 2 clinical trial evaluating serlopitant and Placebo for Prurigo Nodularis. Completed, enrolled 128 participants across 15 sites.
Detailed Summary
The purpose of this study is to demonstrate whether or not VPD-737, an NK1 receptor antagonist is safe and effective for treatment of prurigo nodularis versus placebo.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPrurigo Nodularis
CountriesGermany
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartJul 2014
First PostedJul 2014
Primary CompletionMay 2016
Study CompletionJun 2016
TodayJul 2026
First PostedJul 22, 2014
Enrollment StartJul 9, 2014
Primary CompletionMay 27, 2016
Study CompletionJun 10, 2016
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 11.9 years ago
Interventions
serlopitantdrug
NK1 receptor antagonist
Placebodrug
Placebo